Skip to content

Return on assets at other companies

Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
-36.4%-3.4pp
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-49.7%+2.2pp
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
6.8%+5.6pp
Precigen logo
PrecigenPGEN
-152.9%+61.4pp
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
-11%-4.9pp
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
-76.4%+67.2pp

Other financials

Income statement

See full
Revenue$53.0K-97.3%
Operating income-$14.9M-88.7%
Net income-$15.8M-92.6%
EPS (diluted)-$1.20-62.2%

Balance sheet

See full
Cash & equivalents$206.4M+173%
Total debt$584.0K
Total equity$232.3M+318%
Total assets$263.8M+232%

Cash flow

See full
Operating cash flow-$10.9M-60.5%
CapEx--100%
Free cash flow-$2.7M+72.0%

Valuation

See full
Market cap$1.7B+468%
Enterprise value$1.5B
P/S41.6×

Profitability

See full
Operating margin-183.2%-13.5pp
Net margin71.7%+40.4pp
FCF margin-99.8%-34.2pp

Returns & leverage

See full
Return on equity-34.2%
Debt / equity
Current ratio28.9×+20.0×

Where this comes from

Calculated from Palvella Therapeutics’s reported figures.

Based on trailing twelve months.

The official record: Palvella Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Palvella Therapeutics's return on assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Palvella Therapeutics's return on assets?
Palvella Therapeutics (PVLA) reported return on assets of -28.7% in Q1 2026.
How has Palvella Therapeutics's return on assets changed year-over-year?
Palvella Therapeutics's return on assets increased by 32.2% year-over-year, from -42.4% to -28.7%.
What is the long-term trend for Palvella Therapeutics's return on assets?
Over 5 years (2020 to 2025), Palvella Therapeutics's return on assets has grown at a 13.3% compound annual growth rate (CAGR), from -30.3% to -56.5%.
What does return on assets mean?
Trailing-twelve-month net income divided by average total assets. Measures how efficiently the asset base generates profit, independent of how those assets are financed. Computed as net income over average total assets — note this is OpenCapital's standard definition and may differ from data vendors that use alternative numerators.